ISSN: 2320-480X
Manuscript Submission

The Journal of Phytopharmacology, 2022;11(1):17-23 ;   DOI:10.31254/phyto.2022.11104

Review Article

Recent Development of Anticancer Agents

Satendra Kumar1 , Himanshi Gupta2

1. Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak124001, Haryana, India
2. Advance College of Biotech and Paramedical Science, Kanpur- 209217, Uttar Pradesh, India

*Author to whom correspondence should be addressed.

Received: 29th November, 2021 / Accepted: 22nd January, 2021

Abstract


Cancer is the unwanted growth of the cell, which is developed trillion of the cells. It may be either Cancerous or Non-Cancerous. The aetiology involves the propagation of Cancer, defective DNA, or Mutation in DNA because of distinct Factors (Physical, Chemical, Biology, and Others). There is various kind of cancer (such as Carcinoma, Sarcoma, Myeloma, leukaemia and Lymphoma etc.). The sign and symptoms involve in Cancer (Such fever, loss of appetite, weight loss, thickening or lump in the body and unusual upset stomach or difficulty and swelling). Now a days the treatment is used in treatment of cancer (such as Gene therapy, Surgery, Chemotherapy, Radiation, Immunotherapy and Stem cell transplant). Cancer is an ancient disease, that evidence obtained from Egyptian papyri. In 2021 Epidemiology study of Cancer represent the data related to the Incidence of Cancer higher in Men compare to Women, specially (Prostate and Breast and remaining other). There are lots of Chemical compounds and Monoclonal antibodies developed in the Laboratory to treat various kinds of cancer. In which some chemical compounds and Monoclonal antibodies had been granted Approval by FDA in 2020 for Marketing. We are represented in this paper, FDA approved compound 2020 with its pharmacological study, chemical structure and the dose of compound that is available in Market.

Keywords

Chemical compounds, Anticancer Agents, Monoclonal antibodies.


HOW TO CITE THIS ARTICLE

Kumar S, Gupta H. Recent Development of Anticancer Agents, J Phytopharmacology 2022; 11(1):17-23. doi: 10.31254/phyto.2021.11104

Creative Commons (CC) License-

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (http://creativecommons.org/licenses/by/4.0/).

Copyright

Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

Technical Support

×